Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428671 | 0.89 | HPGD (0.50) | HPGDERN1ALDH1A1LMNATSHR | |
| SCHEMBL31428711 | 0.88 | GRM2 (0.51) | HPGDERN1ALDH1A1LMNATSHR | |
| SCHEMBL31428749 | 0.87 | ALDH1A1 (0.46) | HPGDRIPK1ALDH1A1LMNATSHR | |
| SCHEMBL31428987 | 0.86 | RIPK1 (0.44) | HPGDRIPK1ERN1ALDH1A1MKNK1 | |
| SCHEMBL24977234 | 0.86 | RIPK1 (0.44) | HPGDRIPK1ERN1MKNK1MKNK2 | |
| SCHEMBL31428928 | 0.86 | RIPK1 (0.44) | HPGDRIPK1ERN1MKNK1MKNK2 | |
| SCHEMBL31428784 | 0.85 | MAPT (0.52) | HPGDRIPK1ERN1ALDH1A1LMNA | |
| SCHEMBL31428481 | 0.84 | ERN1 (0.52) | HPGDERN1ALDH1A1LMNATSHR | |
| SCHEMBL31428976 | 0.83 | PDCD1 (0.43) | HPGDRIPK1ALDH1A1LMNATSHR | |
| SCHEMBL31428712 | 0.82 | GRM2 (0.49) | HPGDERN1ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | HPGD 4233/4885RIPK1 546/4885ERN1 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.